Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by Baylor1965on Apr 14, 2011 9:46am
532 Views
Post# 18429803

RE: RE: sharing some thoughts

RE: RE: sharing some thoughtsYes. I'm giving SCT 2 years on the stroke alone. I won't panic or budge on my position until then. Having said this,  I don't think SSS will be at these levels for 2 years 'cause there will be news from the TBI and the MS studies that will push us higher. In addition, if a financial partner for the stroke study is announced (without significant dilution), that should take us higher too. 

Sometimes I feel that a when a specific news release is released it is is like looking at a grain of sand and trying to figure out what the beach looks like. Time will tell on this one.
Bullboard Posts